Deucravacitinib

FDA approvals rise 49% in 2023; CRISPR’s gene editing therapy sees light of day

In 2022, when the US Food and Drug Administration (FDA) was reeling under the impact of the pandem

FDA’s drug approvals drop 26% due to Covid; okays three costly gene therapies in H2

The year 2022 saw the lowest number of drug approvals by the US Food and Drug Administration (FDA)